logo
Share SHARE
FONT-SIZE Plus   Neg

Cytokinetics Reports Results From Phase II Clinical Trials Evaluating CK-2017357

Cytokinetics, Inc. (CYTK) announced encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

Jeremy Shefner, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, concluded that CK-2017357 appeared to be safe and well-tolerated dosed daily at 125 mg, 250 mg, and 375 for two weeks, and that encouraging trends were observed in the ALSFRS-R and MVV. As expected, plasma concentrations of CK-2017357 were unaffected by co-administration with riluzole, while riluzole levels increased during co-administration with CK-2017357.

Adverse events and clinical assessments during treatment with CK-2017357 appeared similar, with or without co-administration of riluzole at the reduced dose of 50 mg daily. Dizziness, the most commonly reported adverse event, was mostly mild and generally began and resolved early after initiating treatment.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A search has been launched for a dog that was placed aboard a wrong WestJet flight and ended up in Hamilton. The labradoodle named Cooper was mistakenly put on a flight to Hamilton and got off its leash in the Ontario city after it was taken out of its kennel by airline staff for a walk. Network management services provider Real Matters Inc. has filed preliminary prospectus for initial public offering in Canada. The filing is done with Ontario Securities Commission. According to Bloomberg, the Canadian real estate data firm is planning to raise around C$125 million or $96 million. Struggling women's apparel retailer Bebe Stores Inc. will close all its stores by the end of May 2017. In a filing with the Securities and Exchange Commission on Friday, Brisbane, California-based Bebe said it expects to incur an impairment charge of about $20 million as a result of the store closures.
comments powered by Disqus
Follow RTT